



| CERTIFICATE NO. | LAB SAMPLE ID | ISSUE DATE  | REPORT STATUS |
|-----------------|---------------|-------------|---------------|
| COA-2026-0186   | 20260800225   | 03 SEP 2026 | FINAL         |

## 01 CLIENT & PRODUCT INFORMATION

|                     |                    |                      |                          |
|---------------------|--------------------|----------------------|--------------------------|
| Client organization | Aurevia Bioscience | Client contact       | support@aureviabilio.com |
| Product name        | PT-141             | Client lot / batch   | 00011/0011               |
| Label claim         | 10 mg              | Lab sample ID        | 20260800225 (A, B, C)    |
| Sample matrix       | Lyophilized        | Quantity received    | 3                        |
| Container / closure | Vial w/Crimp       | Condition on receipt | Intact                   |
| Date received       | 21 Aug 2026        | Testing period       | 28 Aug 2026              |
| Storage condition   | Ambient            | Route / intended use | RUO                      |

## 02 ANALYTICAL TEST RESULTS | Purity, identification and net content

| Analysis                                           | Method / SOP      | Instrumentation       | Result                                            | Units   | Acceptance criterion                                        | Status |
|----------------------------------------------------|-------------------|-----------------------|---------------------------------------------------|---------|-------------------------------------------------------------|--------|
| Purity<br>(Average purity calculated from 3 vials) | UPLC-UV           | Acquity UPLC/PDA      | 99.76 AVG                                         | % area  | >99%                                                        | PASS   |
| Identification                                     | UPLC-MS           | Waters Quattro Series | Conforms                                          | —       | Ionization profile match w/standard across all vials tested | PASS   |
| Net content                                        | Quantitative UPLC | Acquity UPLC/PDA      | Vial 1 – 10.21<br>Vial 2 – 10.14<br>Vial 3- 10.62 | mg/vial | ±10%                                                        | PASS   |


## 03 SUPPORTING ANALYTICAL EVIDENCE

PT-141 LOT00011/BATCH0011 10mg

20260800225 | RT 9.77 min | Area 65418

20260800225B | RT 9.78 min | Area 64104

20260800225C | RT 9.77 min | Area 69598




UV CHROMATOGRAM

PT-141 LOT00011/BATCH0011 10mg

20260800225 531 (9.815) Cm (529:541)

Scan ES+  
4.94e7



MASS SPECTRUM / SPECTRA



04 ENDOTOXIN ANALYSIS | Recombinant Factor C (rFC) fluorescence assay

|                    |                                                                                                       |                        |                              |
|--------------------|-------------------------------------------------------------------------------------------------------|------------------------|------------------------------|
| Method             | Recombinant Factor-c                                                                                  | Instrument / asset ID  | Molecular Devices Gemini XPS |
| Assay / reagent    | bioMerieux EndoZyme II                                                                                | Standard               | Kit-integrated               |
| Sample preparation | Reconstitution in Endotoxin Free Water                                                                | Run / plate ID         | 0828P1-AVQC20260800225       |
| Product limit      | 0.5 EU/mL (AV Analytics applies 2x USP limit for H2O, no USP endotoxin limit applies to RUO products) | Maximum valid dilution | 1:100                        |

| Parameter                         | Result                                    | Acceptance criterion     | Units          | Status |
|-----------------------------------|-------------------------------------------|--------------------------|----------------|--------|
| Endotoxin                         | Vial 1 0.20<br>Vial 2 0.26<br>Vial 3 0.24 | <0.5                     | EU/mL          | PASS   |
| Positive product control recovery | 67                                        | 50-200                   | %              | PASS   |
| Negative control                  | Non-Detect                                | <0.005                   | EU/mL          | PASS   |
| Standard curve / assay validity   | .98                                       | Correlation factor >0.94 | R <sup>2</sup> | PASS   |

05 AUTHORIZATION | Review, decision rule and release

|                         |                      |                    |                                                      |
|-------------------------|----------------------|--------------------|------------------------------------------------------|
| Analyst                 | Jason Snitker        | Technical reviewer | Vanessa Montoya, PhD                                 |
| Authorized signatory    | Vanessa Montoya, PhD | Decision rule      | Document complete, fields correct, analysis reviewed |
| Deviations / qualifiers | None                 | Amendment history  | NA                                                   |

**Report conditions:** Results are analytical findings for the item tested and do not constitute an endorsement of product safety, efficacy or regulatory status. Unless otherwise stated, this certificate may be reproduced only in full with written approval from AV Analytics.